| Dr Akram Kholoki, MD | |
|
3800 Saint Mary Rd Ste 202, Valparaiso, IN 46383-3986 | |
| (219) 286-3788 | |
| (219) 286-3791 |
| Full Name | Dr Akram Kholoki |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 36 Years |
| Location | 3800 Saint Mary Rd Ste 202, Valparaiso, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164598504 | NPI | - | NPPES |
| 90000561 | Other | BLUE SHIELD OF IL | |
| 060044331 | Other | RAILROAD MEDICARE | |
| 000000180622 | Other | BLUE CROSS BLUE SHIELD IN | |
| 200139560 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 01046098A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary Medical Center Inc | Hobart, IN | Hospital |
| Northwest Health - Porter | Valparaiso, IN | Hospital |
| Indiana University Health Starke Hospital | Knox, IN | Hospital |
| Community Hospital | Munster, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Care Network Inc | 3678737012 | 360 |
News Archive
Pharmatek Laboratories has announced the opening of its new 34,000 sq. ft. facility at 7330 Carroll Road, San Diego, California 92121.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.
Health researchers predict that the transmission of dengue could decrease in a future warmer climate, countering previous projections that climate change would cause the potentially lethal virus to spread more easily.
Texas Sen. Ted Cruz's winding, marathon speech on the Senate floor and aimed at bringing attention to efforts to block money for Obamacare's implementation but may have little effect.
› Verified 2 days ago
| Entity Name | Community Care Network Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457610487 PECOS PAC ID: 3678737012 Enrollment ID: O20120614000331 |
News Archive
Pharmatek Laboratories has announced the opening of its new 34,000 sq. ft. facility at 7330 Carroll Road, San Diego, California 92121.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.
Health researchers predict that the transmission of dengue could decrease in a future warmer climate, countering previous projections that climate change would cause the potentially lethal virus to spread more easily.
Texas Sen. Ted Cruz's winding, marathon speech on the Senate floor and aimed at bringing attention to efforts to block money for Obamacare's implementation but may have little effect.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Akram Kholoki, MD 3800 Saint Mary Rd Ste 202, Valparaiso, IN 46383-3986 Ph: (219) 286-3788 | Dr Akram Kholoki, MD 3800 Saint Mary Rd Ste 202, Valparaiso, IN 46383-3986 Ph: (219) 286-3788 |
News Archive
Pharmatek Laboratories has announced the opening of its new 34,000 sq. ft. facility at 7330 Carroll Road, San Diego, California 92121.
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.
Health researchers predict that the transmission of dengue could decrease in a future warmer climate, countering previous projections that climate change would cause the potentially lethal virus to spread more easily.
Texas Sen. Ted Cruz's winding, marathon speech on the Senate floor and aimed at bringing attention to efforts to block money for Obamacare's implementation but may have little effect.
› Verified 2 days ago
Dr. Mazen Zaitoon, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 85 East United States 6 Frontage, Valparaiso, IN 46383 Phone: 219-983-8300 | |
Douglas Adolph Mazurek, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1101 Glendale Blvd, Suite 103, Valparaiso, IN 46383 Phone: 219-464-9054 Fax: 219-465-1749 | |
Michael Christopher Hansen, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 85 E Us Highway 6, Valparaiso, IN 46383 Phone: 219-464-9054 Fax: 219-465-1749 | |
John Dougherty, Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 56 Willow St, Valparaiso, IN 46383 Phone: 219-309-7254 | |
Dr. Akshay R. Trivedi, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2206 Roosevelt Rd Ste A, Valparaiso, IN 46383 Phone: 219-464-2285 | |
George E Sloan, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2600 Roosevelt Rd, Valparaiso, IN 46383 Phone: 219-464-1620 Fax: 219-477-4565 | |
Dr. Jay Shah, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 85 E Us Highway 6 Ste 300, Valparaiso, IN 46383 Phone: 219-983-6300 Fax: 219-263-7620 |